BMO Capital Upgrades Salix Pharmaceuticals (SLXP) to Outperform

February 24, 2010 8:26 AM EST Send to a Friend
BMO Capital upgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Market Perform to Outperform. Price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login